Home » ReGen Announces Data From CMI Feasibility Study
ReGen Announces Data From CMI Feasibility Study
ReGen Biologics, an orthopedic products company that develops, manufactures and markets innovative products for human tissue repair in the U.S. and abroad, announced that five-year follow-up data from its feasibility study regarding the company's patented Collagen Meniscus Implant (CMI) has been published.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May